Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160910 · ClinicalTrials.gov registry record · Phase 2
5HTP Regulation Of Asthma In Children
A Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04160910: Recruiting Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization, sponsored by Indiana University.
NCT04160910 is a Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization that is actively recruiting participants, run by Indiana University. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04160910, a Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a placebo. This will be decided randomly. Later in the study subjects will crossover to the other group.There are 5 study visits over the course of about 12 weeks.
Primary Outcome
Pulmonary function testing will be performed at Baseline, Day 28, and Day 49, and Day 77
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 5-Hydroxytryptophan
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-11 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT04160910 shows while recruiting
NCT04160910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Mild or Moderate Asthma With Allergic Sensitization appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04160910 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04160910 about?
NCT04160910 is a clinical study titled "5HTP Regulation Of Asthma In Children". The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a plac...
What is the current status of trial NCT04160910?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-02-11. Estimated completion is 2026-06-30.
What conditions does trial NCT04160910 study?
This clinical trial studies the following conditions: Mild or Moderate Asthma With Allergic Sensitization.
What interventions are being tested in trial NCT04160910?
The interventions under investigation include: Placebo (DRUG), 5-Hydroxytryptophan (DRUG).
Who is sponsoring clinical trial NCT04160910?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160910 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04160910's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI